TY - JOUR
T1 - Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells
AU - Mortenson, Eric D.
AU - Park, Saegwang
AU - Jiang, Zhujun
AU - Wang, Shengdian
AU - Fu, Yang Xin
PY - 2013/3/15
Y1 - 2013/3/15
N2 - Purpose: Targeting oncogenic receptors with antibodies has been thought to suppress tumor growth mainly by interrupting oncogenic signals. Recently, the essential role for adaptive immunity, and CD8+ T cells in particular, has been established as a major factor for anti-HER2/neu-mediated tumor regression. However, the role of CD4+ T cells is still being defined. The purpose of this study was to explore whether and to what extent CD4 + T cells are involved in mediating the effects of anti-HER2/neu therapy. Experimental Design: The role of CD4+ T cells was examined using a transplant model of the rat HER2/neu-overexpressing cell line TUBO. Tumor-bearing mice were treated with anti-neu therapy in conjunction with CD4 depletion or CD40L blockade. The effects of CD4 depletion on the antitumor response were examined by tumor growth analysis and enzyme-linked immunospot (ELISPOT). Results: In addition to CD8+ T cells, CD4+ T cells are also essential for anti-neu antibody-mediated tumor regression, but B cells are not required. The role for CD4+ cells is necessary throughout anti-neu therapy and not limited to helping CD8+ T cells. Expression of IFN-γ is necessary for anti-neu therapy and IFN-γ induces MHC-II expression inTUBOcells promoting direct recognition byCD4 + T cells. Furthermore, intratumoral depletion of CD4+ T cells or blockade of the activating cell-surface protein CD40L inhibits the antitumor response. Conclusions: This study reveals the essential role of CD4+ T cell for anti-neu-mediated tumor regression.
AB - Purpose: Targeting oncogenic receptors with antibodies has been thought to suppress tumor growth mainly by interrupting oncogenic signals. Recently, the essential role for adaptive immunity, and CD8+ T cells in particular, has been established as a major factor for anti-HER2/neu-mediated tumor regression. However, the role of CD4+ T cells is still being defined. The purpose of this study was to explore whether and to what extent CD4 + T cells are involved in mediating the effects of anti-HER2/neu therapy. Experimental Design: The role of CD4+ T cells was examined using a transplant model of the rat HER2/neu-overexpressing cell line TUBO. Tumor-bearing mice were treated with anti-neu therapy in conjunction with CD4 depletion or CD40L blockade. The effects of CD4 depletion on the antitumor response were examined by tumor growth analysis and enzyme-linked immunospot (ELISPOT). Results: In addition to CD8+ T cells, CD4+ T cells are also essential for anti-neu antibody-mediated tumor regression, but B cells are not required. The role for CD4+ cells is necessary throughout anti-neu therapy and not limited to helping CD8+ T cells. Expression of IFN-γ is necessary for anti-neu therapy and IFN-γ induces MHC-II expression inTUBOcells promoting direct recognition byCD4 + T cells. Furthermore, intratumoral depletion of CD4+ T cells or blockade of the activating cell-surface protein CD40L inhibits the antitumor response. Conclusions: This study reveals the essential role of CD4+ T cell for anti-neu-mediated tumor regression.
UR - http://www.scopus.com/inward/record.url?scp=84875187620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875187620&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-12-2522
DO - 10.1158/1078-0432.CCR-12-2522
M3 - Article
C2 - 23363817
AN - SCOPUS:84875187620
SN - 1078-0432
VL - 19
SP - 1476
EP - 1486
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 6
ER -